Biomarker testing has become central to ovarian cancer care. Measuring CA-125 and other biomarkers supports diagnosis, monitoring, and treatment decisions, while genetic testing for BRCA mutations identifies patients who may benefit from PARP inhibitors. Biomarker testing is a fast-growing segment of the ovarian cancer diagnostics and therapeutics market, and it is reshaping clinical practice.

The market is being driven by expanding use of biomarker testing, growing adoption of genetic testing for hereditary risk, development of companion diagnostics for targeted therapies, and increasing awareness among clinicians. According to ovarian cancer diagnostics and therapeutics market analysis, biomarker testing is projected to reach around USD 1.5 billion by 2035, supported by expanding clinical applications. Growth is driven by the shift toward precision oncology.

Innovation includes multi-marker panels, liquid biopsy approaches, and AI-assisted interpretation.

Challenges include variability in test performance, cost, and access.

Yet the trend is clear: biomarker testing will continue to grow, and the market is expected to benefit substantially.

People Also Ask

Q: What biomarkers are used in ovarian cancer?
A: CA-125 is the most widely used biomarker, alongside HE4 and other emerging markers.

Q: Why is BRCA testing important in ovarian cancer?
A: BRCA mutations identify patients who may benefit from PARP inhibitor therapy and inform family risk assessment.

Tags: #BiomarkerTesting #CA125 #BRCATesting #PrecisionOncology #OvarianCancer #MarketDrivers